Clinical trial registry record

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 16, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05473715
Last registry update
October 16, 2024
Status
Terminated
Phase
Phase 4
Sponsor
Bayer
Enrollment
3
Countries
Canada, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
3
Population
ALL · 50 Years
Duration
2023-04-25 to 2023-07-11
Intervention
Aflibercept(BAY86-5321, Eylea)
Comparator
Treat and extend (T&E) 2 week adjustment
Outcomes measured
Change in Best-corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letters) — Approximat…; Number of Intravitreal (IVT) Aflibercept Injections — Approximately 11 weeks; Number of Patients Achieving Pre-defined Treatment Intervals — Approximately 11 weeks; Change in BCVA (ETDRS Letters) — Approximately 11 weeks; Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TE…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON